Form 8-K - Current report:
SEC Accession No. 0001213900-22-008685
Filing Date
2022-02-22
Accepted
2022-02-22 16:06:28
Documents
14
Period of Report
2022-02-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea155999-8k_immucell.htm   iXBRL 8-K 27854
2 PRESS RELEASE OF IMMUCELL CORPORATION DATED FEBRUARY 22, 2022 ea155999ex99-1_immucell.htm EX-99.1 47486
3 GRAPHIC ex99-1_001.jpg GRAPHIC 4147
  Complete submission text file 0001213900-22-008685.txt   262621

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20220222.xsd EX-101.SCH 3033
5 XBRL LABEL FILE iccc-20220222_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE iccc-20220222_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT ea155999-8k_immucell_htm.xml XML 3484
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 22658070
SIC: 2835 In Vitro & In Vivo Diagnostic Substances